Article Figures & Data
Tables
- Table 1
Demographics and clinical parameters of the patients
Parameter Result (%) Female:Male 19:9 Age* 47.8±9.1, 28–60 Patients with diabetes 2 (~7) Patients with hyperlipidemia 4 (~14) Total amount of cannabis (g)/month* 22.21±3.6, 20–30 % THC 6.75±4, 1–15 % CBD 12.1±4.2, 6–20 Oil:Flowers 21:7 Type of use Sublingual 21 (75%) Smoking 5 (~18%) Vaping 2 (~7) Indication Fibromyalgia 21 (75) Osteoarthritis 5 (~18) CRPS 2 (~7) CBD, cannabidiol; CRPS, chronic regional pain syndrome; THC, delta-9- tetrahydrocannabinol.
- Table 2
Metabolic parameters of the patients prior and 3 months following MC consumption
Parameter Result (%) P value Prior to MC use Following MC use Weight (kg)* 77.4±10.3, 66–112 78.2±10.2, 68–111 0.07 Glucose (mg/dL)* 101.2±18.5, 81–158 104.6±18.7, 80–150 0.272 HabA1c (%)* 6.09±1.35, 5.1–11.5 5.76±0.6, 5–6.8 0.123 Insulin resistance* 57.6±35.7, 19.4–135.7 68.5±58.4, 16.3–252 0.328 Cholesterol (mg/dL)* 179.4±41.8, 99–286 174.6±32.1, 102–242 0.954 Triglycerides (mg/dL)* 150.6±52.1, 60–270 154.2±74.6, 68–425 0.372 LDL (mg/dL)* 102.1±27.4, 42–138 107.3±34.1, 48–189 0.687 HDL (mg/dL)* 44.6±11.1, 26–71 33.8±10.7, 28–69 0.21 Serum cortisol (nmole/L)* 407.4±94.3, 264–577 388.6±97.8, 258–570 0.652 Uric acid (mg/dL)* 5.12±1.99, 2.6–8.6 5.14±1.84, 2.4–7.5 0.612 *Mean±SD, range.
HDL, high-density lipoprotein;LDL, low-density lipoprotein.
Vol 70 Issue 2
Table of Contents
